全文获取类型
收费全文 | 52334篇 |
免费 | 2877篇 |
国内免费 | 532篇 |
专业分类
耳鼻咽喉 | 309篇 |
儿科学 | 2285篇 |
妇产科学 | 1366篇 |
基础医学 | 3819篇 |
口腔科学 | 693篇 |
临床医学 | 4190篇 |
内科学 | 9818篇 |
皮肤病学 | 514篇 |
神经病学 | 1432篇 |
特种医学 | 1375篇 |
外科学 | 7291篇 |
综合类 | 4648篇 |
一般理论 | 2篇 |
预防医学 | 6460篇 |
眼科学 | 516篇 |
药学 | 2996篇 |
18篇 | |
中国医学 | 629篇 |
肿瘤学 | 7382篇 |
出版年
2023年 | 639篇 |
2022年 | 1180篇 |
2021年 | 1917篇 |
2020年 | 1466篇 |
2019年 | 4892篇 |
2018年 | 4176篇 |
2017年 | 2463篇 |
2016年 | 1139篇 |
2015年 | 1230篇 |
2014年 | 2938篇 |
2013年 | 2502篇 |
2012年 | 2103篇 |
2011年 | 2213篇 |
2010年 | 1698篇 |
2009年 | 1615篇 |
2008年 | 1714篇 |
2007年 | 1484篇 |
2006年 | 1141篇 |
2005年 | 952篇 |
2004年 | 848篇 |
2003年 | 663篇 |
2002年 | 439篇 |
2001年 | 458篇 |
2000年 | 383篇 |
1999年 | 367篇 |
1998年 | 303篇 |
1997年 | 312篇 |
1996年 | 250篇 |
1995年 | 196篇 |
1994年 | 191篇 |
1993年 | 129篇 |
1992年 | 92篇 |
1991年 | 78篇 |
1990年 | 61篇 |
1989年 | 80篇 |
1988年 | 54篇 |
1987年 | 49篇 |
1985年 | 1066篇 |
1984年 | 1517篇 |
1983年 | 1137篇 |
1982年 | 1259篇 |
1981年 | 1176篇 |
1980年 | 1025篇 |
1979年 | 1126篇 |
1978年 | 1030篇 |
1977年 | 715篇 |
1976年 | 915篇 |
1975年 | 812篇 |
1974年 | 724篇 |
1973年 | 743篇 |
排序方式: 共有10000条查询结果,搜索用时 48 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
6.
《Transfusion and apheresis science》2022,61(4):103488
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection. 相似文献
7.
8.
《Bulletin du cancer》2023,110(2):145-150
9.
10.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献